PRODUCT DISCONTINUATION NOTIFICATION COULD BE ADDED TO HOUSE FDA REFORM BILL; REP. BURR IS SAID TO BE CONSIDERING COMPROMISE ON ANTIBIOTIC EXCLUSIVITY
Executive Summary
A provision to require manufacturers to provide notice of discontinuance of products used to treat serious or life threatening conditions could be added to the House FDA reform measure (HR 1411) prior to a full committee markup set for Sept. 25, House Commerce/Health Subcommittee Chairman Bilirakis (R-Fla.) indicated at a subcommittee markup of the legislation Sept. 17.